Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents

Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity

(2013) D. Rudnicka et al.   BLOOD

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

(2013) D J DeAngelo et al.   LEUKEMIA

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines

(2012) M. Lemoine et al.   BLOOD

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma

(2012) P.-C. Tsai et al.   CLINICAL CANCER RESEARCH

Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma

(2012) Jasmine Zain   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma

(2012) S-S Wenzel et al.   LEUKEMIA

Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

(2012) A Vilas-Zornoza et al.   LEUKEMIA

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®)

(2012) Simon J Harrison et al.   Epigenomics

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

(2011) M. Kalac et al.   BLOOD

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

(2011) R Pili et al.   BRITISH JOURNAL OF CANCER

Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas

(2011) Elizabeth A. Brem et al.   BRITISH JOURNAL OF HAEMATOLOGY

The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors

(2011) Ádám Jóna et al.   EXPERIMENTAL HEMATOLOGY

Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma

(2011) F. C. Eberle et al.   HAEMATOLOGICA

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

(2011) Mark Kirschbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study

(2011) Catherine Thieblemont et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517

(2011) Mark H. Kirschbaum et al.   LEUKEMIA & LYMPHOMA

Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

(2011) G. Dasmahapatra et al.   MOLECULAR CANCER THERAPEUTICS

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells

(2010) CE Tiffon et al.   BRITISH JOURNAL OF PHARMACOLOGY

Histone deacetylase inhibitors in Hodgkin lymphoma

(2010) Daniela Buglio et al.   INVESTIGATIONAL NEW DRUGS

Tethering of Intercellular Adhesion Molecule on Target Cells Is Required for LFA-1-Dependent NK Cell Adhesion and Granule Polarization

(2010) C. C. Gross et al.   JOURNAL OF IMMUNOLOGY

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

(2010) R Shimizu et al.   LEUKEMIA

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

(2008) D. Buglio et al.   BLOOD

Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

(2008) S. H. Olejniczak et al.   CLINICAL CANCER RESEARCH

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH